Alea A Mills

Prof. Alea A Mills

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GHGuy Horev
Guy Horev
JEJacob Ellegood
Jacob Ellegood
JLJason P. Lerch
Jason P. Lerch
YSYoung-Eun E. Son
Young-Eun E. Son
LMLakshmi Muthuswamy
Lakshmi Muthuswamy
AMAlea A Mills
Alea A Mills
Recurrent copy number variations (CNVs) of human 16p11.2 have been associated with a variety of developmental/neurocognitive syndromes. In particular, deletion of 16p11.2 is found in patients with autism, developmental delay, and obesity. Patients with deletions or duplications have a wide range of clinical features, and siblings carrying the same deletion often have diverse symptoms. To study the consequence of 16p11.2 CNVs in a systematic manner, we used chromosome engineering to generate mice harboring deletion of the chromosomal region corresponding to 16p11.2, as well as mice harboring the reciprocal duplication. These 16p11.2 CNV models have dosage-dependent changes in gene expression, viability, brain architecture, and behavior. For each phenotype, the consequence of the deletion is more severe than that of the duplication. Of particular note is that half of the 16p11.2 deletion mice die postnatally; those that survive to adulthood are healthy and fertile, but have alterations in the hypothalamus and exhibit a “behavior trap” phenotype—a specific behavior characteristic of rodents with lateral hypothalamic and nigrostriatal lesions. These findings indicate that 16p11.2 CNVs cause brain and behavioral anomalies, providing insight into human neurodevelopmental disorders.

17 August 2005 in Genes & Development
Verified
Journal Article
Open access
PDF file
WKWilliam M. Keyes
William M. Keyes
YWYing Wu
Ying Wu
HVHannes Vogel
Hannes Vogel
XGXuecui Guo
Xuecui Guo
SLScott W. Lowe
Scott W. Lowe
AMAlea A Mills
Alea A Mills
The p53 tumor suppressor plays a key role in organismal aging. A cellular mechanism postulated to drive the aging process is cellular senescence, mediated in part by p53. Although senescent cells accumulate in elderly individuals, most studies have relied on correlating in vitro senescence assays with in vivo phenotypes of aging. Here, using two different mouse models in which the p53-related protein p63 is compromised, we demonstrate that cellular senescence and organismal aging are intimately linked and that these processes are mediated by p63 loss. We found that p63+/- mice have a shortened life span and display features of accelerated aging. Both germline and somatically induced p63 deficiency activates widespread cellular senescence with enhanced expression of senescent markers SA-β-gal, PML, and p16INK4a. Using an inducible tissue-specific p63 conditional model, we further show that p63 deficiency induces cellular senescence and causes accelerated aging phenotypes in the adult. Our results thus suggest a causative link between cellular senescence and aging in vivo, and demonstrate that p63 deficiency accelerates this process.

8 November 2009 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
XGXuecui Guo
Xuecui Guo
WKWilliam M. Keyes
William M. Keyes
CPCristian Papazoglu
Cristian Papazoglu
JZJohannes Zuber
Johannes Zuber
WLWangzhi Li
Wangzhi Li
AMAlea A Mills
Alea A Mills

24 September 2010 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
AMAlea A Mills
Alea A Mills

1 February 2011 in Cell Stem Cell
Verified
Journal Article
Closed access
WKWilliam M. Keyes
William M. Keyes
MPMatteo Pecoraro
Matteo Pecoraro
VAVictoria Aranda
Victoria Aranda
EVEmma Vernersson-Lindahl
Emma Vernersson-Lindahl
WLWangzhi Li
Wangzhi Li
AMAlea A Mills
Alea A Mills

15 April 2008 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ABAnindya Bagchi
Anindya Bagchi
AMAlea A Mills
Alea A Mills
Genomic analyses of late-stage human cancers have uncovered deletions encompassing 1p36, thereby providing an extensive body of literature supporting the idea that a potent tumor suppressor resides in this interval. Although several genes have been proposed as 1p36 candidate tumor suppressors, convincing evidence that their encoded products protect from cancer has been scanty. A recent functional study identified chromodomain helicase DNA-binding protein 5 (CHD5) as a novel tumor suppressor mapping to 1p36. Here, we discuss evidence supporting the tumor-suppressive role of CHD5. Together, these findings suggest that strategies designed to enhance CHD5 activity could provide novel approaches for treating a broad range of human malignancies. [Cancer Res 2008;68(8):2551–6]